HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    

Zacks Equity Research
Zacks Rank can tell you which stocks to buy and sell. Zacks Equity Research tells you why. Click here to learn more.
Quote:
Login Free Membership
Search:

 
Analyst Blog  

Regenerate with Regeneron

January 26, 2009 | Comments: 0
Recommended this article (1)
Print    Share

Regeneron Pharmaceuticals, Inc. (REGN - Analyst Report) is a biopharmaceutical company engaged in the development and marketing of therapeutic medicines for the treatment of serious medical conditions. Its lead candidates are VEGF-Trap for the treatment of cancers, eye diseases, and IL-1 Trap for CAPS and gout.

The company recently received the FDA approval of Arcalyst for CAPS [CIAS1-Associated Periodic Syndrome, a rare genetic disorder]. It also has a number of pre-clinical drug candidates for other disorders.

The company made impressive progress in recent months in terms of clinical advances and business developments. We maintain our Buy rating on its shares with a price target of $28.

Read the full analyst report on REGN



Email

Print

Share

RSS

Rate Pos

Rate Neg

Comment
Read/Post Comments (0) | Recommended this article (1)
 Posting Comment...
There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]
Comments (Limit 1000 Characters - Used: 0)
Display Name: Email Address:  
 Loading Comments...
Be the first to comment on this article!
Best Stocks. Best Insight. Join Now...it's FREE!
Over 550,000 investors look forward to the timely insights in our email newsletter; Zacks Profit from the Pros. In each daily issue you will find:
  • Free  Four Zacks #1 Rank "Strong Buy" Stocks
  • Free  Timely Market Commentary
  • Free  Wealth Management Tips
  • Free  Profitable Strategy Screens
  • Free  Bull and Bear Stocks of the Day
Zacks FREE Registration

More Zacks Resources

Market Summary Nov 26, 2009 09:38 am ET
DJIA 10464.4  30.69 0.29%
NASD 2176.05  6.87 0.32%
S&P 500 1110.63  4.98 0.45%
Sponsored Links